×
Featured
Want to learn more about Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!
Program Committee
-
Stephen Knowles, MD, MRCP Chief Medical Officer
Halozyme Therapeutics, United States -
Lesley Wise, PhD, MSc Managing Director
Wise Pharmacovigilance and Risk Management, Ltd, United Kingdom -
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Patient Safety Officer
Bristol-Myers Squibb Company, United States -
Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
FDA, United States -
E. Stewart Geary, MD MD, Global Safety Officer
Eisai Co., Ltd., Japan -
Lisa Melanie Harinstein, PharmD Team Leader, Division of Pharmacovigilance, FDA
FDA, United States -
Jeremy Jokinen, PhD, MS Vice President and Head, Safety Evidence and Sciences
Bristol-Myers Squibb Company, United States -
Annette Stemhagen, DrPH, PhD, FISPE Chief Science Officer
UBC, United States -
Sarah Vaughan Head of Vigilance Operations
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
IQVIA, United States -
Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States -
Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP Strategy
Consultant, United Kingdom -
William Gregory, PhD Senior Director, Safety and Risk Management
Pfizer Inc, United States -
Valerie E. Simmons, MD, FFPM Senior Medical Fellow, Global Patient Safety
Eli Lilly and Company Ltd, United Kingdom
Have an account?